Skip to main content
Livermore
Livermore
ZHEN

Sagimet Biosciences Inc.

SGMT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001400118

In the last 90 days, Sagimet Biosciences Inc. insiders filed 0 open-market purchases and 5 sales; 122 institutions reported holding it in 13F filings for Q2 2026, worth $394.3M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Holders of 5% or more of SGMT

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Sagimet Biosciences Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of SGMT
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G7.80%4.75M sharesNewJul 30, 20261 filingJul 30, 2026SEC
Balyasny Asset Management LLC13G5.93%3.63M sharesNewAug 14, 20261 filingAug 14, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

23 Schedule 13D and 13G filings on Sagimet Biosciences Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on SGMT
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20266:09 AM ETBalyasny Asset Management LLCand 4 others13G5.93%3.63M sharesNewJun 30, 2026SEC
Jul 30, 202611:18 AM ETBlackRock, Inc.13G7.80%4.75M sharesNewJun 30, 2026SEC
Dec 18, 20254:50 PM ETKPCB Pandemic & Bio Defense Fund LLCand 1 other13G/A0.00%0 shares–Below 5%Dec 18, 2025SEC
Nov 14, 20254:16 PM ETWoodline Partners LP13G/A4.80%1.50M shares−3.50 ppfrom 8.30%Below 5%Sep 30, 2025SEC
Aug 14, 20255:03 PM ETPoint72 Asset Management, L.P.and 2 others13G/A0.00%0 shares−5.70 ppfrom 5.70%Below 5%Jun 30, 2025SEC
Aug 14, 202511:58 AM ETWoodline Partners LP13G8.30%2.55M sharesNewJun 30, 2025SEC
Jun 24, 202511:11 AM ETAP11 Ltdand 1 other13G/A4.90%1.50M shares−0.50 ppfrom 5.40%Below 5%Jun 24, 2025SEC
May 20, 20257:34 PM ETAP11 Ltdand 1 other13G5.40%1.65M sharesNewDec 31, 2023SEC
May 15, 20254:28 PM ETPoint72 Asset Management, L.P.and 2 others13G/A5.70%1.76M shares–Mar 31, 2025SEC
May 13, 20254:15 PM ETNew Enterprise Associates 13 LPand 7 others13G/A0.00%0 shares–Below 5%Mar 31, 2025SEC
Feb 14, 20255:09 PM ETBlue Owl Capital Holdings LP13G/A4.32%1.32M shares–Below 5%Dec 31, 2024SEC
Nov 14, 2024Blue Owl Capital Holdings LP13GOld format–New–SEC
Nov 14, 2024Baker Bros. Advisors LP13G/AOld format–––SEC
Nov 14, 2024Point72 Asset Management, L.P.13G/AOld format–––SEC
Nov 14, 2024Hillhouse Investment Management, Ltd.13G/AOld format–––SEC
Mar 11, 2024FMR LLC13G/AOld format–––SEC
Feb 14, 2024Baker Bros. Advisors LP13GOld format–New–SEC
Feb 14, 2024KPCB Pandemic & Bio Defense Fund LLC13GOld format–New–SEC
Feb 14, 2024New Enterprise Associates 13 LP13GOld format–New–SEC
Feb 14, 2024Hillhouse Investment Management, Ltd.13GOld format–New–SEC
Feb 9, 2024FMR LLC13G/AOld format–––SEC
Feb 5, 2024Point72 Asset Management, L.P.13GOld format–New–SEC
Sep 11, 2023FMR LLC13GOld format–New–SEC

Form 144: proposed insider sales

1 notice from officers, directors and other affiliates planning to sell Sagimet Biosciences Inc. shares, newest first.

Form 144 notices for SGMT
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Jul 23, 20244:24 PM ETGeorge KembleDirector · Officer23.6K$73.0KJul 23, 202410b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC